Literature DB >> 10070840

Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo.

S Tsimikas1, W Palinski, S E Halpern, D W Yeung, L K Curtiss, J L Witztum.   

Abstract

BACKGROUND: Oxidatively modified low-density lipoprotein (LDL) is present in atherosclerotic but not normal arteries and plays a crucial role in the pathogenesis and adverse consequences of atherosclerotic lesions. We previously generated a series of monoclonal antibodies (MoAb) against oxidation-specific neo-epitopes formed during the oxidative modification of LDL. MDA2, a prototype MoAb, recognizes malondialdehyde-lysine epitopes (eg, in malondi-aldehyde-modified LDL) within atherosclerotic lesions. We describe the in vivo characteristics of MDA2 and initial noninvasive imaging studies of atherosclerosis in rabbits.
METHODS: To assess the in vivo specificity of MDA2 for atherosclerotic lesions, iodine 125-MDA2 was intravenously injected into 7 LDL-receptor deficient Watanabe heritable hyperlipidemic (WHHL) and 2 normal New Zealand white (NZW) rabbits, and the aortic plaque uptake was evaluated 24 hours later. 125I-Halb, an isotype-matched irrelevant MoAb that binds to human albumin, was injected into 5 WHHL and 2 NZW rabbits as a control. Aortic autoradiography was performed, and the mean uptake of MoAbs was measured as the percent injected dose per gram aortic tissue. Gamma camera imaging was then carried out in 7 WHHL rabbits and 2 NZW rabbits with 99mTc-MDA2. Imaging was carried out at 10 minutes and at 12 or 24 hours. Malondialdehyde-LDL was then injected to clear the blood pool signal, and final images were obtained 2 hours later.
RESULTS: Mean uptake of 125I-MDA2 in the entire aorta was 17.4-fold higher in WHHL than in NZW aortas (P < .001), and 2.8-fold higher than 125I-Halb in WHHL aortas. 125I-MDA2 also had higher specificity for lesioned areas than 125I-Halb (plaque/normal ratio 6.3 vs 2.9, P < .001). Autoradiograph of aortas of 125I-MDA2-injected WHHL rabbits revealed uptake in lipid-stained lesions with absence of signal in adjacent normal arterial tissue. Immunostaining of WHHL lesions, which accumulated MDA2 as noted on autoradiography, revealed that uptake was highest in areas with abundant foam cells and in lipid-rich necrotic core areas. Autoradiograph of aortas from NZW rabbits injected with 125I-MDA2 did not yield any visible signal. Planar gamma camera in vivo scintigraphy revealed a visible signal in 4/7 WHHL rabbits, which was confirmed by aortic Sudan staining.
CONCLUSION: Radiolabeled MDA2 shows excellent in vivo uptake and specificity for atherosclerotic lesions containing abundant oxidation-specific epitopes. The in vivo imaging studies suggest that noninvasive imaging of oxidation-rich atherosclerotic lesions with radiolabeled MDA2 may be feasible in human beings with optimization of the imaging methods.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070840     DOI: 10.1016/s1071-3581(99)90064-8

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  57 in total

Review 1.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

2.  Indium-111-labeled platelet scintigraphy in carotid atherosclerosis.

Authors:  E Minar; H Ehringer; R Dudczak; R Schöfl; M Jung; R Koppensteiner; R Ahmadi; G Kretschmer
Journal:  Stroke       Date:  1989-01       Impact factor: 7.914

3.  Rapid blood clearance of biotinylated IgG after infusion of avidin.

Authors:  V V Sinitsyn; A G Mamontova; Y Y Checkneva; A A Shnyra; S P Domogatsky
Journal:  J Nucl Med       Date:  1989-01       Impact factor: 10.057

4.  Radionuclide imaging of experimental atherosclerosis with nonspecific polyclonal immunoglobulin G.

Authors:  A J Fischman; R H Rubin; B A Khaw; P B Kramer; R Wilkinson; M Ahmad; M Needelman; E Locke; N D Nossiff; H W Strauss
Journal:  J Nucl Med       Date:  1989-06       Impact factor: 10.057

5.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death.

Authors:  M J Davies; A Thomas
Journal:  N Engl J Med       Date:  1984-05-03       Impact factor: 91.245

6.  Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture.

Authors:  P K Shah; E Falk; J J Badimon; A Fernandez-Ortiz; A Mailhac; G Villareal-Levy; J T Fallon; J Regnstrom; V Fuster
Journal:  Circulation       Date:  1995-09-15       Impact factor: 29.690

7.  Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments.

Authors:  J Narula; A Petrov; C Bianchi; C C Ditlow; B C Lister; J Dilley; I Pieslak; F W Chen; V P Torchilin; B A Khaw
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

Review 8.  Coronary artery screening by electron beam computed tomography. Facts, controversy, and future.

Authors:  N D Wong; R C Detrano; D Abrahamson; J M Tobis; J M Gardin
Journal:  Circulation       Date:  1995-08-01       Impact factor: 29.690

9.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.

Authors:  W Palinski; T Koschinsky; S W Butler; E Miller; H Vlassara; A Cerami; J L Witztum
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

10.  Generation, characterization, and histochemical application of monoclonal antibodies selectively recognizing oxidatively modified apoB-containing serum lipoproteins.

Authors:  A Hammer; G Kager; G Dohr; H Rabl; I Ghassempur; G Jürgens
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-05       Impact factor: 8.311

View more
  37 in total

Review 1.  New developments in the detection of vulnerable plaque.

Authors:  M Naghavi; M Madjid; M R Khan; R M Mohammadi; J T Willerson; S W Casscells
Journal:  Curr Atheroscler Rep       Date:  2001-03       Impact factor: 5.113

2.  Strategic targeting of atherosclerotic lesions.

Authors:  J Narula; R Virmani; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1999 Jan-Feb       Impact factor: 5.952

3.  In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes.

Authors:  Karen C Briley-Saebo; Tuyen Hoang Nguyen; Alexander M Saeboe; Young-Seok Cho; Sung Kee Ryu; Eugenia R Volkova; Eugenia Volkava; Stephen Dickson; Gregor Leibundgut; Philipp Wiesner; Philipp Weisner; Simone Green; Florence Casanada; Yury I Miller; Walter Shaw; Joseph L Witztum; Zahi A Fayad; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2012-02-07       Impact factor: 24.094

Review 4.  Targeting the vulnerable plaque: the evolving role of nuclear imaging.

Authors:  John R Davies; James F Rudd; Tim D Fryer; Peter L Weissberg
Journal:  J Nucl Cardiol       Date:  2005 Mar-Apr       Impact factor: 5.952

Review 5.  Antibodies for molecular imaging in the cardiovascular system.

Authors:  Ban-An Khaw
Journal:  J Nucl Cardiol       Date:  2005 Sep-Oct       Impact factor: 5.952

6.  The atherosclerotic plaque: a healthy challenge to the limits of nuclear imaging.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2005 May-Jun       Impact factor: 5.952

7.  Identification of interleukin-2 for imaging atherosclerotic inflammation.

Authors:  Zahi A Fayad; Vardan Amirbekian; Jean-François Toussaint; Valentin Fuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

8.  Fluorodeoxyglucose and calcium uptake in the vascular wall: clinically relevant or sugar-coated pill?

Authors:  Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

Review 9.  Oxidized low-density lipoprotein biomarkers in atherosclerosis.

Authors:  Sotirios Tsimikas
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

Review 10.  Molecular imaging in cardiovascular disease: Which methods, which diseases?

Authors:  Jonathan R Lindner; Albert Sinusas
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.